Cardiol Therapeutics Inc. announced on April 29, 2025, the nomination of Dr. Timothy J. Garnett to stand for election to the company's Board of Directors. Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 years of experience, including two decades at Eli Lilly and Company, where he served as Chief Medical Officer from 2008 until his retirement in 2021.
During his tenure at Eli Lilly, Dr. Garnett led the successful development of therapeutics in women's health, endocrinology, and neuroscience, resulting in multiple global commercial launches. His extensive background includes leadership roles in clinical development, portfolio management, medical affairs, regulatory strategy, and safety functional areas. This experience is expected to be instrumental as Cardiol advances its clinical pipeline.
Guillermo Torre-Amione, Chair of Cardiol Therapeutics, stated that Dr. Garnett's wealth of industry experience and strategic vision, particularly in clinical development, will be invaluable. His nomination comes as the company marks a significant milestone with the recent initiation of patient enrollment in its pivotal Phase III MAVERIC trial. Dr. Garnett's election is anticipated to further guide the company's strategic priorities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.